Fundz

Alzamend Neuro, Inc. reported raising $232,000 in an initial SEC Form D filing, from an offering of $2 Million

PUBLIC · ALZNApr 23, 2019$231.5K of $2M raised

Amount Raised

$232,000

$232,000 sold, per SEC Form D (first sale Apr 23, 2019)

Round Type

Pre-Seed

AtlantaBiotechnologyHealth CareScience And Engineering

Who else raised in Science And Engineering and Biotechnology around the same time

Companies in the same sectors as Alzamend Neuro that raised within 45 days of this round, from Fundz verified event records.

  • Sherlock Biosciences raised $33M on April 25, 2019.
  • Cardiff Oncology raised $1.5M (Seed) on April 10, 2019.
  • Enliven Therapeutics raised $44M on March 29, 2019.
  • KayoThera, Inc. raised $750K (Seed) on June 5, 2019.
  • SpyGlass Pharma, Inc. raised $6M on June 5, 2019.
  • HealthSnap raised $2.5M (Seed) on June 3, 2019.

Who to call at Alzamend Neuro, and when

A new round usually means Alzamend Neuro is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Alzamend Neuro raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Alzamend Neuro, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Alzamend Neuro. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Alzamend Neuro

Location

Atlanta, Georgia, United States

About

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Alzamend Neuro raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsJames, Deputy General Counsel and Vice Preside…See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Alzamend Neuro's next move

See what Strategic adds

Alzamend Neuro raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.